These results suggest that early treatment with a TrkB agonist during juvenile and adolescent stages may have prophylactic and therapeutic effects on behavioral abnormalities in several psychiatric disorders, including schizophrenia and substance abuse. This evidence concerns the gene NTRK2 and schizophrenia.